<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20699">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02837432</url>
  </required_header>
  <id_info>
    <org_study_id>19771</org_study_id>
    <nct_id>NCT02837432</nct_id>
  </id_info>
  <brief_title>The Effect of Cortisol Administration on Neural Correlates of Emotion in Depression</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is good evidence to suggest that the pathological version of sadness that people with
      Major Depression experience could be caused by the failure of the hormone cortisol to
      properly inhibit sadness-related brain activity in the subgenual cingulate cortex. This
      project investigates if the subgenual cingulate cortex has become insensitive to cortisol in
      patients with depression and tests for variants of the cortisol receptor genes that could
      predispose individuals to develop cortisol insensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sadness-induced subgenual cingulate activity as measured by functional magnetic resonance imaging.</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Healthy individuals will receive both the placebo and hydrocortisone interventions in a randomized order</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Depression</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Individuals with depression will receive both the placebo and hydrocortisone interventions in a randomized order</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrocortisone acetate</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
    <other_name>Cortef</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Healthy</arm_group_label>
    <arm_group_label>Depression</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Participants must have no Axis 1 mental disorder

          -  Participants with depression must meet minimum severity levels (Hamilton &gt;7)

          -  All participants must weight less than 280 pounds for the purposes of MRI scanning

        Exclusion Criteria:

        In order to protect against risk associated with taking Hydrocortisone, all participants
        must not have any of the following:

          -  Psychotropic medications

          -  Recent surgery

          -  Endocrine disorders

          -  Liver disease

          -  Kidney disease

          -  Thyroid disorder

          -  History of malaria

          -  Tuberculosis

          -  Osteoporosis

          -  Glaucoma/cataracts

          -  Chronic expressed infections (herpes --including ocular herpes, HIV, etc.)

          -  History of congestive heart failure

          -  History of recurring seizures

          -  Stomach Ulcers

          -  Comorbid psychosis

          -  Current use of illicit drugs

          -  High Blood pressure

        In order to protect against risks associated with MRI scanning participants must not
        be/have any of the following:

          -  &gt;280 lbs

          -  In-dwelling ferrous metals

          -  Left Handed

          -  Abnormal Hearing

          -  Claustrophobic

          -  Head injury with loss of consciousness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 19, 2016</lastchanged_date>
  <firstreceived_date>July 15, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Keith Sudheimer</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Cortisol</keyword>
  <keyword>Sadness</keyword>
  <keyword>Genetics</keyword>
  <keyword>Stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
